However, no changes in either liver macroscopic appearance or weight were detected in sorafenib (100 mg kg−1) (a kinase inhibitor approved for treating primary liver cancer) treated AKT/c-Met HCC (see ESI Fig. S2†). This evidence concerns the gene AKT1 and hepatocellular carcinoma.